Condition
Diabetes Mellitus, Type 2
Diabetic Peripheral Neuropathy
Locations
Canada, Denmark, France, Norway, Spain
Start date
29/01/2025
Identifiers
Trial ID
NN9388-7864,
NCT number NCT06797869,
Eudract number Not Available
NCT number NCT06797869,
Eudract number Not Available
Summary
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Trial Overview:
Treatment
DRUG: CagriSema (Cagrilintide B and Semaglutide I)
DRUG: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Study type
INTERVENTIONAL
Trial duration
Jan 29 2025 - Aug 21 2026
Participants
134
Phase
II
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.